United Therapeutics Stock Price Prediction
| UTHR Stock | USD 367.36 3.03 0.83% |
Oversold Vs Overbought
78
Oversold | Overbought |
Quarterly Earnings Growth 0.188 | EPS Estimate Next Quarter 6.57 | EPS Estimate Current Year 24.514 | EPS Estimate Next Year 27.8222 | Wall Street Target Price 382.2943 |
Using United Therapeutics hype-based prediction, you can estimate the value of United Therapeutics from the perspective of United Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
United Therapeutics Hype to Price Pattern
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of United Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about United Therapeutics.
The fear of missing out, i.e., FOMO, can cause potential investors in United Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying United because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
United Therapeutics after-hype prediction price | USD 367.36 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
United |
United Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of United Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in United Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of United Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
United Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting United Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on United Therapeutics' historical news coverage. United Therapeutics' after-hype downside and upside margins for the prediction period are 365.63 and 369.09, respectively. We have considered United Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
United Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of United Therapeutics is based on 3 months time horizon.
United Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as United Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading United Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with United Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.11 | 1.73 | 0.61 | 0.13 | 12 Events / Month | 13 Events / Month | In about 12 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
367.36 | 367.36 | 0.00 |
|
United Therapeutics Hype Timeline
United Therapeutics is at this time traded for 367.36. The entity has historical hype elasticity of 0.61, and average elasticity to hype of competition of -0.13. United is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is about 31.06%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at 0.11%. %. The volatility of related hype on United Therapeutics is about 142.56%, with the expected price after the next announcement by competition of 367.23. About 98.0% of the company outstanding shares are owned by institutional investors. The book value of United Therapeutics was at this time reported as 136.74. The company has Price/Earnings To Growth (PEG) ratio of 1.57. United Therapeutics recorded earning per share (EPS) of 22.77. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 23rd of September 2009. Given the investment horizon of 90 days the next forecasted press release will be in about 12 days. Check out United Therapeutics Basic Forecasting Models to cross-verify your projections.United Therapeutics Related Hype Analysis
Having access to credible news sources related to United Therapeutics' direct competition is more important than ever and may enhance your ability to predict United Therapeutics' future price movements. Getting to know how United Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how United Therapeutics may potentially react to the hype associated with one of its peers.
United Therapeutics Additional Predictive Modules
Most predictive techniques to examine United price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for United using various technical indicators. When you analyze United charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About United Therapeutics Predictive Indicators
The successful prediction of United Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as United Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of United Therapeutics based on analysis of United Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to United Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to United Therapeutics's related companies. | 2023 | 2024 (projected) | Dividend Yield | 0.0129 | 0.0114 | Price To Sales Ratio | 4.42 | 4.2 |
Story Coverage note for United Therapeutics
The number of cover stories for United Therapeutics depends on current market conditions and United Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that United Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about United Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
United Therapeutics Short Properties
United Therapeutics' future price predictability will typically decrease when United Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of United Therapeutics often depends not only on the future outlook of the potential United Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. United Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 49.7 M | |
| Cash And Short Term Investments | 3 B |
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.